BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-106@catalystbrief.girapphe.com
DTSTAMP:20261117T181544Z
LAST-MODIFIED:20261117T181544Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261102
SUMMARY:Readout: Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd. — A16
 6 [Nov 2026]
DESCRIPTION:Phase 3 primary completion: A Study of A166 Versus Trastuzumab 
 Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastati
 c Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy.\nS
 ource: https://clinicaltrials.gov/study/NCT06968585\nhttps://catalystbrief
 .girapphe.com/e/106?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/106?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
